

Press Release

Revenue up by 21% and PAT up by 18% (4th Quarter FY 2026 Consolidated Results)

Mumbai, 5th May, 2026: Ajanta Pharma Ltd., a specialty pharmaceutical formulation company today reported its excellent performance for 4th quarter and year ended 31st March 2026.

Q4 FY 2026 performance highlights (compared to Q4 FY 2025):

- Revenue from operations at **Rs. 1,422 cr.** against Rs. 1,170 cr.; **up 21%**.
- EBITDA at **Rs. 333 cr.** against Rs. 297 cr.; EBITDA at 23%; **up 12%**.
- The mark-to-market forex loss stood at Rs. 42 cr. Excluding this impact, EBITDA stood at **Rs. 375 cr.**, reflecting a 26% growth, with an **EBITDA margin of 26%**.
- Profit after tax at **Rs. 267 cr.** against Rs. 225 cr.; PAT at 19%; **up 18%**.

FY 2026 performance highlights (compared to FY 2025):

- Revenue from operations at **Rs. 5,453 cr.** against Rs. 4,648 cr.; **up 17%**.
- EBITDA at **Rs. 1,395 cr.** against Rs. 1,260 cr.; EBITDA at 26%; **up 11%**.
- The mark-to-market forex loss stood at Rs. 103 cr. Excluding this impact, EBITDA stood at **Rs. 1,498 cr.**, reflecting a 18% growth, with an **EBITDA margin of 27%**.
- Profit after tax at **Rs. 1,056 cr.** against Rs. 920 cr.; PAT at 19%; **up 15%**.
- ROCE stood at a healthy level of 33% and RONW at 25%.

Segment wise performance:

(Rs. cr.)

Markets	Q4		Gwth%	FY		Gwth%
	FY 2025	FY 2026		FY 2025	FY 2026	
Branded Generics						
India	₹ 369	₹ 404	9%	₹ 1,452	₹ 1,654	14%
Asia	₹ 303	₹ 274	(10%)	₹ 1,191	₹ 1,175	(1%)
Africa	₹ 133	₹ 182	37%	₹ 750	₹ 861	15%
Sub-Total	₹ 805	₹ 859	7%	₹ 3,394	₹ 3,690	9%
US Generic	₹ 325	₹ 505	56%	₹ 1,047	₹ 1,557	49%
Africa Institution	₹ 28	₹ 48	71%	₹ 147	₹ 160	9%
Total	₹ 1,158	₹ 1,412	22%	₹ 4,588	₹ 5,407	18%

As per **IQVIA MAT March 2026**, our India branded generic performance exceeded IPM growth by **33%**. The higher growth came from new launches, which exceeded IPM by **68%** & volumes, which exceeded IPM by **34%**.

Therapy	Growth %	
	IPM	Ajanta
Cardiology	14%	7%
Ophthalmology	9%	14%
Dermatology	7%	14%
Pain Management	8%	12%
Overall	10%	13%

ANDA status as at the end of FY 2026 is as below:

Particulars	FY 2026
Filed	5
Approval received	4
Launched	4
Total ANDA's commercialized	49
Awaiting approval with US FDA	19
Tentative approval	6

R&D expense:

(Rs. cr.)

Particulars	FY 2025	FY 2026	% to Revenue
Q4	₹ 53	₹ 70	5%
FY	₹ 161	₹ 252	5%

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa. Company has ground presence in each of these 30+ countries. Many of company's products are 1st to market and are leading in their sub-therapeutic segments. Company also has presence in USA in generic business and institution business in Africa.

Company's state of the art R&D centre is in Mumbai. Company has 7 world class manufacturing facilities located in India.

For the last 3 financial years, company has posted healthy Revenue and PAT CAGR of 14%.

Earnings Conference Call

The Company will host an Earnings Conference Call at 16:30 hrs. IST (19:00 hrs. SST/HKT, 12:00 hrs. BST, 07:00 hrs. US ET), during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.ajantapharma.com.

Dial-in Information

Date and Time	May 05, 2026 at 16:30 – 17:30 hrs IST 19:00 – 20:00 hrs SST/HKT 12:00 – 13:00 hrs BST 07:00 – 08:00 hrs US ET
Dial-in Numbers	
Diamond pass link for faster access	Click here to register
Universal Access	Primary Access: (+91 22 6280 1542) (+91 22 7115 8372)
International Toll Free	USA: 18667462133 UK: 08081011573 Hong Kong: 800964448 Singapore: 8001012045

For convenience and faster connectivity to the conference, kindly follow below steps:

1. Register through the Diamond pass link.
2. You will receive a calendar invite along with a passcode and a PIN number. The passcode and PIN will be activated 30 minutes prior to the conference scheduled time.
3. Dial the 'conference Dial-in number' you will receive on your email.
4. On system prompt dial the PASSCODE followed by # key.
5. On system prompt enter the PIN followed by # key.
6. If the line gets disconnected, you need to dial the 'conference dial-in number' again and follow the necessary steps.

Playback of Earnings Conference Call audio:

Playback of the earnings call will be available 120 minutes after the end of the call on our website (www.ajantapharma.com).

For more details visit www.ajantapharma.com

For regular updates follow us on x.com – <https://x.com/AjantaPharmaLtd>

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 6060 9706 Email: rajeev.agarwal@ajantapharma.com

Abhineet Kumar Tel: +91 22 6060 9721 Email: abhineet.kumar@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331

Corporate Identity Number (CIN): L24230M9M979PLC022059

Safe Harbour Statement

Statement of Consolidated Audited Financial Results for the quarter and year ended 31 March 2026

₹ in Crore

Particulars	Quarter ended			Year ended	
	31-Mar-26	31-Dec-25	31-Mar-25	31-Mar-26	31-Mar-25
	Audited	Unaudited	Audited	Audited	Audited
Income					
Revenue from operations	1,421.64	1,374.84	1,170.41	5,452.86	4,648.10
Other income (Refer note 4)	61.43	24.97	18.11	172.07	94.50
Total Income	1,483.07	1,399.81	1,188.52	5,624.93	4,742.60
Expenses					
Cost of materials consumed	256.76	235.07	190.96	916.51	846.60
Purchases of stock-in-trade	71.35	53.55	80.18	229.79	249.80
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(23.30)	(2.36)	12.28	37.46	(25.64)
Employee benefits expense	340.72	330.52	279.78	1,291.15	1,089.69
Finance costs	2.36	5.10	6.07	16.11	20.73
Depreciation and amortisation expense	45.37	43.51	39.78	173.14	144.11
Other expenses (Refer note 4)	442.70	375.82	310.06	1,583.12	1,228.15
Total Expenses	1,135.96	1,041.21	919.11	4,247.28	3,553.44
Profit before and after exceptional items but before tax	347.11	358.60	269.41	1,377.65	1,189.16
Tax Expense					
Current Tax	61.40	86.88	61.96	300.08	312.30
Deferred Tax	19.01	(2.05)	(17.81)	21.57	(43.53)
Profit for the period	266.70	273.77	225.26	1,056.00	920.39
Other Comprehensive Income (OCI)					
Items that will be reclassified subsequently to profit or loss	15.83	2.32	3.47	29.39	7.68
Income tax relating to items that will be reclassified subsequently to profit or loss	-	-	-	-	-
Items that will not be reclassified subsequently to profit or loss	3.51	0.28	(2.19)	(0.48)	(8.96)
Income tax relating to items that will not be reclassified to profit or loss	(1.23)	(0.09)	0.76	0.17	3.13
Other Comprehensive Income / (loss) for the year, net of tax	18.11	2.51	2.04	29.08	1.85
Total Comprehensive Income for the period	284.81	276.28	227.30	1,085.08	922.24
Paid-up Equity Share Capital (Face value of ₹ 2 each)	25.07	25.07	25.07	25.07	25.07
Other Equity				4,502.02	3,765.22
Earnings Per Share (Face value of ₹ 2 each)					
(a) Basic - in ₹	21.35	21.91	18.00	84.53	73.56
(b) Diluted - in ₹	21.34	21.91	18.00	84.51	73.53

Notes :

- The above consolidated financial results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 5 May 2026. The statutory auditors have expressed an unmodified opinion on the results for the quarter and year ended 31 March 2026. The audit report has been filed with the stock exchange and is available on the company's website.
- The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures upto the third quarter ended 31 December 2025 and 31 December 2024 respectively.
- The consolidated audited financial results of the Company and its wholly owned subsidiaries ("the Group") have been prepared as per Ind AS 110 on "Consolidated Financial Statements". There is no minority interest.

4. Other income / Other expense includes :

₹ in Crore	Quarter ended			Year ended	
	31-Mar-26	31-Dec-25	31-Mar-25	31-Mar-26	31-Mar-25
Foreign exchange gain (in other income)	44.37	8.55	7.06	97.17	28.21
Foreign exchange loss (in other expense)	41.70	-	-	103.04	8.82

5. During the year ended 31 March 2026, 23,525 (previous year 25,325) equity shares of ₹ 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Share Based Incentive Plan, 2019, resulting in an increase in the paid-up share capital by ₹ 47,050 (previous year ₹ 50,650) and securities premium by ₹ 3.50 crores (previous year ₹ 3.84 crores). Under the same plan, 4,300 Cash Settled Stock Appreciation Rights (SARs) were vested and settled in cash and there was no change in the paid-up share capital and securities premium of the company.

6. In August 2025, the Income Tax Authorities carried out search operations at certain premises of the Parent Company. Subsequently, the Parent Company received a notice dated 6 February 2026 under Section 158BC of the Income tax Act, 1961, requiring the Parent Company to file a true and correct return for the block period from 1 April 2019 to 17 November 2025. The Parent Company filed the return for the said block period on 6 April 2026. Pending any subsequent communication from the concerned authorities in this regard, the consequent impact on the consolidated financial results for the year ended 31 March 2026, if any, is currently not ascertainable.

7. Statement of Consolidated Assets and Liabilities

₹ in Crore

Particulars	31-Mar-26 Audited	31-Mar-25 Audited
ASSETS		
Non-current assets		
Property, plant and equipment	1,726.35	1,624.87
Capital work-in-progress	258.05	176.27
Right to use assets	99.02	90.63
Other Intangible assets	41.58	46.52
Financial assets		
Investments	28.50	25.24
Other financial assets	7.99	9.25
Deferred tax assets (net)	188.59	186.43
Income tax assets (net)	7.56	-
Other non-current assets	61.77	12.71
Total non-current assets	2,419.41	2,171.92
Current assets		
Inventories	938.54	903.85
Financial assets		
Investments	559.85	438.71
Trade receivables	1,853.88	1,182.74
Cash and cash equivalents	103.26	175.12
Bank balances other than cash and cash equivalents	1.51	1.12
Loans	1.68	2.54
Other financial assets	8.98	2.32
Other current assets	267.73	123.30
	3,735.43	2,829.70
Assets classified as held for sale	-	13.33
Total current assets	3,735.43	2,843.03
Total assets	6,154.84	5,014.95
EQUITY AND LIABILITIES		
Equity		
Equity share capital	25.07	25.07
Other equity	4,502.02	3,765.22
Total equity	4,527.09	3,790.29
Non-current liabilities		
Financial liabilities		
Lease liabilities	39.42	34.72
Other financial liabilities	1.82	1.05
Other non-current liabilities	1.67	2.00
Provisions	51.15	80.27
Deferred tax liabilities (net)	117.94	110.52
Total non-current liabilities	212.00	228.56
Current liabilities		
Financial liabilities		
Borrowings	211.99	2.59
Trade payables		
(a) total outstanding dues of micro and small enterprises	54.17	21.55
(b) total outstanding dues of creditors other than micro and small enterprises	490.13	432.65
Other financial liabilities	495.82	374.20
Lease liabilities	8.76	10.11
Other current liabilities	119.00	91.12
Provisions	30.39	23.35
Income tax liabilities (net)	5.49	40.53
Total current liabilities	1,415.75	996.10
Total liabilities	1,627.75	1,224.66
Total Equity and Liabilities	6,154.84	5,014.95

8. Statement of Consolidated Cash Flow

₹ in Crore

Particulars	31-Mar-26 Audited	31-Mar-25 Audited
A. Cash flow from operating activities		
Profit before tax	1,377.65	1,189.16
Adjustment for :		
Depreciation and amortisation expense	173.14	144.11
Loss / (gain) on sale / retirement of property, plant and equipment (net)	1.87	0.60
Finance costs	16.11	20.73
Loss / (Gain) on investment at FVTPL	(1.55)	3.65
Loss / (Gain) on fair value of derivative	88.92	8.82
Loss / (Gain) on sale/redemption of Current Investments	(8.70)	(14.99)
Interest income on investments and deposits	(51.60)	(44.08)
Deferred government grant	(0.33)	(0.33)
Equity settled share based payment	1.53	3.88
Unrealised foreign exchange loss / (gain)	(58.14)	(10.31)
Impairment (Gain) / loss on financial assets	2.21	0.03
Operating cash flow before working capital changes	1,541.11	1,301.27
Changes in working capital		
Decrease / (Increase) in trade receivables	(590.84)	80.48
Decrease / (Increase) in other receivable	(158.82)	25.29
Decrease / (Increase) in inventories	(30.95)	(74.51)
(Decrease) / Increase in trade payable	90.79	(8.45)
Increase / (Decrease) in other payable	59.28	115.64
Increase / (Decrease) in provisions	(22.39)	40.48
Cash generated from operating activities	888.18	1,480.20
Net income tax paid	(358.99)	(322.97)
Net cash generated from operating activities	529.19	1,157.23
B. Cash flow from investing activities		
Capital expenditure on property, plant and equipment & intangible assets including capital advances	(365.16)	(317.92)
Proceeds from sale of property, plant and equipment	5.41	1.14
Bank balances not considered as cash and cash equivalents	(0.39)	0.16
Purchase of current investments	(2,659.98)	(2,761.21)
Proceeds from sale of current investments	2,549.09	2,663.48
Income on investments and deposits	45.37	44.08
Investment in Limited Liability Partnership - Non Current Investment	(3.26)	(6.25)
Net cash used in investing activities	(428.92)	(376.52)
C. Cash flow from financing activities		
Proceeds from Issue of Equity Shares (31 March 2026 ₹ 47,050, 31 March 2025 ₹ 50,650)	-	0.01
Proceeds / (repayment) of borrowings (net)	209.40	1.10
Interest paid	(12.80)	(17.31)
Payment of lease liability (includes interest of Rs. 3.31 crores in current year and Rs. 3.43 crores in previous year)	(14.80)	(14.89)
(Payment) for buyback of equity shares	-	(351.34)
Income / (payment) for expenses for buyback of equity shares	-	(1.61)
Dividend paid	(349.72)	(349.37)
Net cash used in financing activities	(167.92)	(733.41)
Net increase / (decrease) in cash and cash equivalents	(67.65)	47.30
Cash and cash equivalents as at the beginning of the year	175.12	129.49
Cash and cash equivalents as at the end of the year	107.47	176.79
Reconciliation of cash and cash equivalents with the Balance sheet		
Cash and cash equivalents as at the end of the year	107.47	176.79
Unrealised loss / (gain) on foreign currency cash and cash equivalents	(4.21)	(1.67)
Cash and cash equivalents restated balance as per balance sheet	103.26	175.12
Figures in brackets indicates outflow.		

9. The Group operates exclusively in one reportable business segment i.e., "Pharmaceuticals".

10. The Financial Results are available on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com.

**Rekha
Shenoy** Digitally signed
by Rekha Shenoy
Date: 2026.05.05
14:55:03 +05'30'

By order of the Board
For Ajanta Pharma Ltd.

Digitally signed by
YOGESH MANNALAL
MANNALAL AGRAWAL
AGRAWAL
Date: 2026.05.05
14:35:57 +05'30'

Yogesh M. Agrawal
Managing Director

Mumbai, 5 May 2026

Statement of Standalone Audited Financial Results for the quarter and year ended 31 March 2026

₹ in Crore

Particulars	Quarter ended			Year ended	
	31-Mar-26	31-Dec-25	31-Mar-25	31-Mar-26	31-Mar-25
	Audited	Unaudited	Audited	Audited	Audited
Income					
Revenue from operations	1,210.53	1,206.59	1,013.94	4,845.92	4,322.04
Other income (Refer note 3)	62.98	25.76	17.93	204.40	119.87
Total Income	1,273.51	1,232.35	1,031.87	5,050.32	4,441.91
Expenses					
Cost of materials consumed	256.77	235.07	190.96	916.52	846.60
Purchases of stock-in-trade	57.99	57.89	56.54	218.06	184.00
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(49.56)	(38.23)	(15.10)	(57.32)	(18.58)
Employee benefits expense	313.49	306.16	257.86	1,194.05	1,010.90
Finance costs	(0.74)	1.87	0.67	2.59	4.60
Depreciation and amortisation expense	44.16	42.38	38.76	168.77	139.93
Other expenses (Refer note 3)	393.79	304.75	274.03	1,376.62	1,094.40
Total Expenses	1,015.90	909.89	803.72	3,819.29	3,261.85
Profit before and after exceptional items but before tax	257.61	322.46	228.15	1,231.03	1,180.06
Tax Expense					
Current Tax	67.33	72.58	39.10	276.61	258.03
Deferred Tax	(7.00)	4.84	(4.38)	7.60	5.14
Profit for the period	197.28	245.04	193.43	946.82	916.89
Other Comprehensive Income (OCI)					
Items that will not be reclassified subsequently to profit or loss	3.51	0.28	(2.19)	(0.48)	(8.96)
Income tax relating to items that will not be reclassified to profit or loss	(1.23)	(0.09)	0.76	0.17	3.13
Other Comprehensive Income / (loss) for the year, net of tax	2.28	0.19	(1.43)	(0.31)	(5.83)
Total Comprehensive Income for the period	199.56	245.23	192.00	946.51	911.06
Paid-up Equity Share Capital (Face value of ₹ 2 each)	25.07	25.07	25.07	25.07	25.07
Other Equity				4,198.46	3,600.24
Earnings Per Share (Face value of ₹ 2 each)					
(a) Basic - in ₹	15.79	19.61	15.46	75.79	73.28
(b) Diluted - in ₹	15.79	19.61	15.45	75.77	73.25

Notes :

- The above standalone results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 5 May 2026. The statutory auditors have expressed an unmodified opinion on the results for the quarter and year ended 31 March 2026. The audit report has been filed with the stock exchange and is available on the company's website.
- The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures upto the third quarter ended 31 December 2025 and 31 December 2024 respectively.
- Other income / Other expense includes :

₹ in Crore	Quarter ended			Year ended	
	31-Mar-26	31-Dec-25	31-Mar-25	31-Mar-26	31-Mar-25
Dividend from subsidiaries (in other income)	-	-	-	36.68	22.28
Foreign exchange gain (in other income)	46.16	9.42	7.29	99.66	32.96
	41.70	-	-	103.04	8.82

- During the year ended 31 March 2026, 23,525 (previous year 25,325) equity shares of ₹ 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Share Based Incentive Plan, 2019, resulting in an increase in the paid-up share capital by ₹ 47,050 (previous year ₹ 50,650) and securities premium by ₹ 3.50 crores (previous year ₹ 3.84 crores). Under the same plan, 4,300 Cash Settled Stock Appreciation Rights (SARs) were vested and settled in cash and there was no change in the paid-up share capital and securities premium of the company.
- In August 2025, the Income Tax Authorities carried out search operations at certain premises of the Company. Subsequently, the Company received a notice dated 6 February 2026 under Section 158BC of the Income tax Act, 1961, requiring the Company to file a true and correct return for the block period from 1 April 2019 to 17 November 2025. The Company filed the return for the said block period on 6 April 2026. Pending any subsequent communication from the concerned authorities in this regard, the consequent impact on the standalone financial results for the year ended 31 March 2026, if any, is currently not ascertainable.

6. Statement of Standalone Assets and Liabilities

₹ in Crore

Particulars	31-Mar-26 Audited	31-Mar-25 Audited
ASSETS		
Non-current assets		
Property, plant and equipment	1,722.63	1,621.61
Capital work-in-progress	258.05	176.27
Right to use assets	81.15	75.04
Other Intangible assets	40.99	45.31
Financial assets		
Investments	46.39	43.13
Other financial assets	6.17	8.14
Income tax assets (net)	5.57	-
Other non-current assets	37.11	8.69
Total non-current assets	2,198.06	1,978.19
Current assets		
Inventories	844.71	739.29
Financial assets		
Investments	559.85	438.71
Trade receivables	1,365.77	1,225.81
Cash and cash equivalents	89.04	48.60
Bank balances other than cash and cash equivalents	1.51	1.12
Loans	1.68	2.54
Other financial assets	8.98	2.32
Other current assets	247.12	108.82
	3,118.66	2,567.21
Assets classified as held for sale	-	8.85
Total current assets	3,118.66	2,576.06
Total assets	5,316.72	4,554.25
EQUITY AND LIABILITIES		
Equity		
Equity share capital	25.07	25.07
Other equity	4,198.46	3,600.24
Total equity	4,223.53	3,625.31
Non-current liabilities		
Financial liabilities		
Lease liabilities	29.58	24.39
Other financial liabilities	1.82	1.05
Other non-current liabilities	1.67	2.00
Provisions	51.15	80.27
Deferred tax liabilities (net)	117.94	110.51
Total non-current liabilities	202.16	218.22
Current liabilities		
Financial liabilities		
Trade payables		
(a) total outstanding dues of micro and small enterprises	54.17	21.55
(b) total outstanding dues of creditors other than micro and small enterprises	417.68	344.72
Other financial liabilities	259.19	158.82
Lease liabilities	5.11	6.78
Other current liabilities	119.00	138.87
Provisions	30.39	23.35
Income tax liabilities (net)	5.49	16.63
Total current liabilities	891.03	710.72
Total liabilities	1,093.19	928.94
Total Equity and Liabilities	5,316.72	4,554.25

7. Statement of Standalone Cash Flow

₹ in Crore

Particulars	31-Mar-26 Audited	31-Mar-25 Audited
A. Cash flow from operating activities		
Profit before tax	1,231.03	1,180.06
Adjustment for :		
Depreciation and amortisation expense	168.77	139.93
Loss / (gain) on sale / retirement of property, plant and equipment (net)	1.87	0.60
Finance costs	2.59	4.60
Dividend from subsidiaries	(36.68)	(22.28)
Loss / (Gain) on investment at FVTPL	(1.55)	3.65
Gain on sale/redemption of Current Investments	(8.70)	(14.99)
Interest income on investment and deposits	(51.04)	(44.34)
Loss / (Gain) on fair value of derivative	88.92	8.82
Deferred government grant	(0.33)	(0.33)
Equity settled share based payment	1.53	4.00
Unrealised foreign exchange loss / (gain)	(58.14)	(10.31)
Impairment (Gain) / loss on financial assets	1.89	0.03
Operating cash flow before working capital changes	1,340.16	1,249.44
Changes in working capital		
Decrease / (increase) in trade receivables	(77.61)	(6.59)
Decrease / (increase) in other receivable	(136.17)	25.44
Decrease / (increase) in inventories	(105.42)	(61.50)
Decrease / (increase) in trade payable	103.69	(17.08)
Increase / (decrease) in other payable	(5.38)	105.43
Increase / (decrease) in provisions	(22.39)	40.49
Cash generated from operating activities	1,096.88	1,335.63
Net income tax paid	(293.06)	(281.83)
Net cash generated from operating activities	803.82	1,053.80
B. Cash flow from investing activities		
Capital expenditure on property, plant and equipment & intangible assets including capital advances	(367.28)	(317.20)
Proceeds from sale of property, plant and equipment	0.50	0.85
Bank balances not considered as cash and cash equivalents	(0.12)	(0.13)
Dividend from subsidiaries	36.68	22.28
Purchase of current investments	(2,659.98)	(2,761.21)
Proceeds from sale of current investments	2,549.10	2,663.48
Income on investments and deposits	44.81	48.58
Investment in Limited Liability Partnership - Non Current Investment	(3.26)	(6.25)
Net cash used in investing activities	(399.55)	(349.60)
C. Cash flow from financing activities		
Proceeds from Issue of Equity Shares (31 March 2026 ₹ 47,050, 31 March 2025 ₹ 50,650)	-	0.01
Interest paid	(0.27)	(1.41)
Payment of lease liability (includes interest of Rs. 2.75 crores in current year and Rs. 3.19 crores in previous year)	(9.63)	(11.99)
Payment for buyback of equity shares	-	(284.99)
Payment of tax on buyback of equity shares	-	(66.35)
Payment for expenses for buyback of equity shares	-	(1.61)
Dividend paid	(349.72)	(349.37)
Net cash used in financing activities	(359.62)	(715.71)
Net increase / (decrease) in cash and cash equivalents	44.65	(11.51)
Cash and cash equivalents as at the beginning of the year	48.60	61.78
Cash and cash equivalents as at the end of the year	93.25	50.27
Reconciliation of cash and cash equivalents with the Balance sheet		
Cash and cash equivalents as at the end of the year	93.25	50.27
Unrealised loss / (gain) on foreign currency cash and cash equivalents	(4.21)	(1.67)
Cash and cash equivalents restated balance as per balance sheet	89.04	48.60
Figures in brackets indicates outflow.		

8. The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals".

9. The Financial Results are available on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com.

Rekha Shenoy
Digitally signed
by Rekha Shenoy
Date: 2026.05.05
14:55:41 +05'30'

By order of the Board
For Ajanta Pharma Ltd.

YOGESH MANNALAL
MANNALAL
AGRAWAL
Digitally signed by
YOGESH MANNALAL
MANNALAL
Date: 2026.05.05
14:37:00 +05'30'

Yogesh M. Agrawal
Managing Director

Mumbai, 5 May 2026